Cover Image
市場調查報告書

Generon (Shanghai) Corporation Ltd. 的產品平台分析

Generon (Shanghai) Corporation Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 277771
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Generon (Shanghai) Corporation Ltd. 的產品平台分析 Generon (Shanghai) Corporation Ltd. - Product Pipeline Review - 2015
出版日期: 2015年12月30日 內容資訊: 英文 26 Pages
簡介

Generon (Shanghai) Corporation Ltd. 是總公司設立於中國的生物科技企業。其開發平台有內含人粒細胞集落刺激因子的重組融合蛋白等,正在開發為嗜中性白血球低下症,及心臟病發作·脊髓神經損傷等造成的急劇性神經原損傷的治療藥。

本報告提供Generon (Shanghai) Corporation Ltd. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Generon (Shanghai) Corporation Ltd. 的基本資料

  • Generon (Shanghai) Corporation Ltd. 概要
  • 主要資訊
  • 企業資料

Generon (Shanghai) Corporation Ltd. :R&D概要

  • 主要的治療範圍

Generon (Shanghai) Corporation Ltd. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Generon (Shanghai) Corporation Ltd. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • IND/CTA登記申請中的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式

Generon (Shanghai) Corporation Ltd. :藥物簡介

  • F-627
  • F-652
  • F-637

Generon (Shanghai) Corporation Ltd. :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Generon (Shanghai) Corporation Ltd. :最新的開發平台情形

Generon (Shanghai) Corporation Ltd. :開發暫停中的計劃

Generon (Shanghai) Corporation Ltd. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07945CDB

Summary

Global Markets Direct's, 'Generon (Shanghai) Corporation Ltd. - Product Pipeline Review - 2015', provides an overview of the Generon (Shanghai) Corporation Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Generon (Shanghai) Corporation Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Generon (Shanghai) Corporation Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Generon (Shanghai) Corporation Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Generon (Shanghai) Corporation Ltd.'s pipeline products

Reasons to buy

  • Evaluate Generon (Shanghai) Corporation Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Generon (Shanghai) Corporation Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Generon (Shanghai) Corporation Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Generon (Shanghai) Corporation Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Generon (Shanghai) Corporation Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Generon (Shanghai) Corporation Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Generon (Shanghai) Corporation Ltd. Snapshot
    • Generon (Shanghai) Corporation Ltd. Overview
    • Key Information
    • Key Facts
  • Generon (Shanghai) Corporation Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Generon (Shanghai) Corporation Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Generon (Shanghai) Corporation Ltd. - Pipeline Products Glance
    • Generon (Shanghai) Corporation Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Generon (Shanghai) Corporation Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Generon (Shanghai) Corporation Ltd. - Drug Profiles
    • F-627
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-652
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-637
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Generon (Shanghai) Corporation Ltd. - Pipeline Analysis
    • Generon (Shanghai) Corporation Ltd. - Pipeline Products by Target
    • Generon (Shanghai) Corporation Ltd. - Pipeline Products by Route of Administration
    • Generon (Shanghai) Corporation Ltd. - Pipeline Products by Molecule Type
    • Generon (Shanghai) Corporation Ltd. - Pipeline Products by Mechanism of Action
  • Generon (Shanghai) Corporation Ltd. - Recent Pipeline Updates
  • Generon (Shanghai) Corporation Ltd. - Dormant Projects
  • Generon (Shanghai) Corporation Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Generon (Shanghai) Corporation Ltd., Key Information
  • Generon (Shanghai) Corporation Ltd., Key Facts
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Indication, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Stage of Development, 2015
  • Generon (Shanghai) Corporation Ltd. - Monotherapy Products in Pipeline, 2015
  • Generon (Shanghai) Corporation Ltd. - Phase II, 2015
  • Generon (Shanghai) Corporation Ltd. - Phase I, 2015
  • Generon (Shanghai) Corporation Ltd. - IND/CTA Filed, 2015
  • Generon (Shanghai) Corporation Ltd. - Preclinical, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Target, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Route of Administration, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Molecule Type, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Generon (Shanghai) Corporation Ltd. - Recent Pipeline Updates, 2015
  • Generon (Shanghai) Corporation Ltd. - Dormant Developmental Projects,2015

List of Figures

  • Generon (Shanghai) Corporation Ltd. - Pipeline by Top 10 Indication, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Stage of Development, 2015
  • Generon (Shanghai) Corporation Ltd. - Monotherapy Products in Pipeline, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Top 10 Target, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Generon (Shanghai) Corporation Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top